BMS-986158,Ruxolitinib,Fedratinib
BMS,Novartis,Incyte
['ca011,023', 'rux,(-crux),(-trux),(-deruxtecan)', 'ruxolitinib', 'ca011-023', 'bms-986158', 'rux,(-crux),(-trux)', 'fedra', 'bms']
watch: haifa kathrin al-ali, md, discusses the safety and efficacy findings from the phase 1/2 ca011-023 trial of bms-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis. #eha2023 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.